Navigation Links
Uroplasty Reports Record Sales for Third Fiscal Quarter and Nine Months Ended December 31, 2007
Date:2/11/2008

financing activities 5,312,735 6,445,974

Effect of exchange rates on cash and cash

equivalents 131,929 3,663

Net increase in cash and cash equivalents 4,095,112 4,151,065

Cash and cash equivalents at beginning of

period 3,763,702 1,563,433

Cash and cash equivalents at end of period $7,858,814 $5,714,498

Supplemental disclosure of cash flow

information:

Cash paid during the period for interest $25,204 $22,011

Cash paid during the period for income taxes 87,900 93,935

Supplemental disclosure of non-cash financing

and investing activities:

Employee retirement savings plan contribution

issued in common shares - 44,385

Property, plant and equipment additions funded

by lessor allowance and classified as deferred

rent - 280,000

Purchase of intellectual property funded by

issuance of stock 4,658,861 -

Non-GAAP Financial Measures. The following table reconciles our non-GAAP financial measures that exclude non cash charges attributed to stock options under SFAS 123 (R), and depreciation and amortization expenses from gross profit, operating expenses and operating loss to our GAAP financial statements above. The non-GAAP financial measures used by management and disclosed by us are not a substitute for, or superior to, financial measures and consolidated financial results calculated in accordance with GAAP, and you should carefully evaluate our reconciliations to non-GAAP. We may calculate our non-GAAP financial measures differently from similarly titled measures used by other companies. Therefore, our non-GAAP financial measures may not be comparable to those used
'/>"/>

SOURCE Uroplasty, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Uroplasty to Host Third Quarter Conference Call on February 11
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Pittsburgh, PA (PRWEB) February 26, 2015 ... March 9 -12, at the Ernest N. Morial ... 919 exhibitors (count as of February 19, 2015) ... community in industrial, academic, and government labs. The ... such as, but not limited to, analytical chemistry; ...
(Date:2/26/2015)... Innovation is more urgent than ... parts of the world and transforming global markets ... manufacturing to health care, disruption is constantly underway. ... socio-political trends shake the foundations of established business ... CEOs to survive the next wave of mega-change. ...
(Date:2/26/2015)... According to a new market report published by ... (Corn, Soybean, Cotton and Others), Synthetic Biology-Enabled Products and ... and Forecast, 2013 – 2019,”the global agricultural biotechnology market ... is expected to reach USD 28,694.1 million by 2019, ... 2019. , Demand for food production has increased ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 Regis Technologies ... the development of oncology drug substances. , Regis Technologies ... of their new Potent Compound Suite (PCS) for 2015. ... 36,000 square foot, cGMP facility in Morton Grove, Illinois. ... manufacturing of potent compounds up to about one kilogram ...
Breaking Biology Technology:Pittcon 2015 Announces Exposition Highlights 2One Million Acts of Innovation Canada Creates Partnership with The Economist Events’ Innovation Forum 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 3Regis Extends cGMP Services to Oncology Market 2
... Funds to Be Used for Phase 1 Clinical Trial ... a privately-held,radiopharmaceuticals company that designs and develops products to ... has raised $13,million in a private offering. Cellectar will ... 1 clinical trial for its lead oncology,product candidate, CLR1404, ...
... WiMAX Broadband Wireless Technology, Will, Provide Free Internet Access to ... ... College, PETACH TIKVA, Israel, January 8 012,Smile.Communications (NASDAQ: ... today announced that it has joined,with Israel,s Ministry of Communications, ...
... and tiny iron-bearing particles to drive healthy cells to ... animals, may lead to a new method of delivering ... in people. , The study team, led by Robert ... Pediatric Cardiology at The Childrens Hospital of Philadelphia, loaded ...
Cached Biology Technology:Cellectar, Inc. Raises $13 Million in Private Offering 2Cellectar, Inc. Raises $13 Million in Private Offering 3Israel's Ministry of Communications, 012 Smile.Communications, Intel and Alvarion Join in Launching WiMAX Initiative for Sderot, a City in the Western Negev 2Israel's Ministry of Communications, 012 Smile.Communications, Intel and Alvarion Join in Launching WiMAX Initiative for Sderot, a City in the Western Negev 3Israel's Ministry of Communications, 012 Smile.Communications, Intel and Alvarion Join in Launching WiMAX Initiative for Sderot, a City in the Western Negev 4Israel's Ministry of Communications, 012 Smile.Communications, Intel and Alvarion Join in Launching WiMAX Initiative for Sderot, a City in the Western Negev 5Researchers use magnetism to target cells to animal arteries 2Researchers use magnetism to target cells to animal arteries 3
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: ... market in general the State of Washington,s ... for a new enrollment and central issuance system for driver,s ... The project planning and development will start in ...
(Date:1/22/2015)... Wis. , Jan. 15, 2015  BellBrook Labs, ... drug discovery, announced the launch of a TR-FRET ... the company,s Transcreener UDP Assay, a high throughput ... The new assay will allow for sensitive detection ...
(Date:1/22/2015)... YORK , Jan. 21, 2015  Analyst Report Issued by ... Card Brands report showed that planet-wide, transactions at merchants on ... while the total number of credit, debit, and prepaid cards ... U.S. were victims of fraudulent card usage in 2012, and ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
... April 2012 -- New techniques for identifying lung cancer ... nanotech ,nose, and a method to examine the cells ... presentations at the 3rd European Lung Cancer Conference (ELCC) ... is vital to improve lung cancer survival rates," commented ...
... new studies that may help doctors tailor lung cancer ... their tumors are being presented at the 3rd European ... of lung cancer treatment is to tailor the treatment ... Christie NHS Foundation Trust in Manchester, UK. "The studies ...
... Patients with advanced non-small cell lung cancer should only ... chemotherapy if their tumor is known to harbor EGFR ... Conference in Geneva, Switzerland. The results of ... that patients with unknown or negative mutation status should ...
Cached Biology News:Early detection techniques offer hope for improved outcomes in lung cancer patients 2Early detection techniques offer hope for improved outcomes in lung cancer patients 3Early detection techniques offer hope for improved outcomes in lung cancer patients 4Advances in personalized medicine for lung cancer 2Advances in personalized medicine for lung cancer 3Advances in personalized medicine for lung cancer 4Advances in personalized medicine for lung cancer 5New analysis helps guide use of erlotinib in advanced non-small cell lung cancer 2New analysis helps guide use of erlotinib in advanced non-small cell lung cancer 3
...
... Edited by R. Edwards ... on all types of immunoassays, ... surface immunoassays and on the ... immunoassays. Essential information is also ...
ANTI S. ENTERID LPS...
B.D. Hames and D.M. Glover (1996) • This issue covers T-Cell antigen receptor genes; T-Lymphocyte signal transduction; B-Cell activation antibody engineering and the complement system and other ...
Biology Products: